NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline. The engagement spans early-phase payload-linker development—already underway—and will advance to cGMP bioconjugation upon commissioning of the new suite.
The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs, sufficient for clinical requirements once the program transitions to cGMP production in the expanded facility. The facility is expected to be operational by the end of Q4FY26, with related bioconjugation work commencing thereafter.
Beyond this, NJ Bio is in advanced discussions with three to four additional customers whose ADC programs are expected to transition to cGMP manufacturing in alignment with the commissioning of the expanded suite. Recently NJ Bio has expanded its linker- payload capabilities with a dedicated lab, completing one GMP campaign with two more underway.
The global ADC market, valued in the billions, is experiencing robust growth driven by rising cancer incidence and increasing demand for targeted immuno-oncology therapies. NJ Bio’s comprehensive single-site CRDMO model-integrating payload-linker synthesis, bioconjugation chemistry, process optimization, analytical characterization, and clinical manufacturing-aligns with the growing preference among global innovators for seamless, end-to-end execution under one roof.
Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: “This investment marks a pivotal milestone in strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster. As a global CRDMO, we’re excited to leverage our strong presence in both the U.S. and India to deliver differentiated value to innovators worldwide.”
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.